{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:06:27Z","timestamp":1793459187100,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T00:00:00Z","timestamp":1669507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T00:00:00Z","timestamp":1669507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Grant-in-Aid for Scientific Research (B) from the Japan Society for the Promotion of Science","award":["21H03178"],"award-info":[{"award-number":["21H03178"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A non-invasive method to evaluate the fibrosis stage and the risk stratification of non-alcoholic fatty liver disease (NAFLD) is required. A total of 416,066 generally healthy subjects who underwent health check-ups between 1990 and 2019 were investigated. Fatty liver prevalence greatly increased from the 1990s (21.9%) to the 2000s (37.1%) but showed no considerable change between 2001\u20132010 (39.2%) and 2011\u20132019 (35.5%). During the 30 years, the rate of high FIB-4 index (\u22652.67) and mean body mass index (BMI) did not markedly change. Fatty liver was significantly associated with BMI, but not with alcohol intake or FIB-4 index. Cox regression analyses for development of chronic hepatitis or liver cirrhosis identified that the risk of developing chronic hepatitis and liver cirrhosis was higher in subjects without fatty liver than in those with it (hazard ratio [HR]=0.09; 95% confidence interval [CI], 0.03\u20130.22,<jats:italic>p<\/jats:italic>\u00a0&lt;0.001 and HR=0.04; 95% CI, 0.01\u20130.26,<jats:italic>p<\/jats:italic>\u00a0=0.001, respectively), and much larger in subjects with a high FIB-4 index (\u2265 2.67) than in those without it (HR=78.6; 95% CI, 29.0\u2013213.1,<jats:italic>p<\/jats:italic>\u00a0&lt;0.001 and HR=5950.7; 95% CI,761.7\u201346,491.4,<jats:italic>p<\/jats:italic>\u00a0&lt;0.001, respectively). Adjusted survival curves for Cox proportional hazards regression further reinforced these results. In conclusion, the FIB-4 index is a useful indicator of chronic hepatitis and liver cirrhosis development in the general population.<\/jats:p>","DOI":"10.1038\/s41598-022-24910-2","type":"journal-article","created":{"date-parts":[[2022,11,27]],"date-time":"2022-11-27T11:29:52Z","timestamp":1669548592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Fibrosis-4 index efficiently predicts chronic hepatitis and liver cirrhosis development based on a large-scale data of general population in Japan"],"prefix":"10.1038","volume":"12","author":[{"given":"Nobutake","family":"Yamamichi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Shimamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Okushin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Matsuzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Yakabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Fujishiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,27]]},"reference":[{"key":"24910_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12876-015-0247-9","volume":"15","author":"K Okushin","year":"2015","unstructured":"Okushin, K. et al. Helicobacter pylori infection is not associated with fatty liver disease including non-alcoholic fatty liver disease: A large-scale cross-sectional study in Japan. BMC Gastroenterol. 15, 25 (2015).","journal-title":"BMC Gastroenterol."},{"key":"24910_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi, Z. M. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64, 73\u201384 (2016).","journal-title":"Hepatology"},{"key":"24910_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"Z Younossi","year":"2018","unstructured":"Younossi, Z. et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat. Rev. Gastroenterol. Hepatol. 15, 11\u201320 (2018).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"24910_CR4","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1002\/hep.30251","volume":"69","author":"Z Younossi","year":"2019","unstructured":"Younossi, Z. et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology 69, 2672\u20132682 (2019).","journal-title":"Hepatology"},{"key":"24910_CR5","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","volume":"66","author":"LA Adams","year":"2017","unstructured":"Adams, L. A., Anstee, Q. M., Tilg, H. & Targher, G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66, 1138\u20131153 (2017).","journal-title":"Gut"},{"key":"24910_CR6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","volume":"149","author":"P Angulo","year":"2015","unstructured":"Angulo, P. et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149, 389\u201397.e10 (2015).","journal-title":"Gastroenterology"},{"key":"24910_CR7","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","volume":"67","author":"H Hagstr\u00f6m","year":"2017","unstructured":"Hagstr\u00f6m, H. et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J. Hepatol. 67, 1265\u20131273 (2017).","journal-title":"J. Hepatol."},{"key":"24910_CR8","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","volume":"156","author":"L Castera","year":"2019","unstructured":"Castera, L., Friedrich-Rust, M. & Loomba, R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 156, 1264-1281.e4 (2019).","journal-title":"Gastroenterology"},{"key":"24910_CR9","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1002\/hep.30842","volume":"70","author":"QM Anstee","year":"2019","unstructured":"Anstee, Q. M. et al. Noninvasive tests accurately identify advanced fibrosis due to NASH: Baseline data from the STELLAR trials. Hepatology 70, 1521\u20131530 (2019).","journal-title":"Hepatology"},{"key":"24910_CR10","doi-asserted-by":"publisher","first-page":"254","DOI":"10.14309\/ajg.0000000000001054","volume":"116","author":"ZM Younossi","year":"2021","unstructured":"Younossi, Z. M. et al. Role of noninvasive tests in clinical gastroenterology practices to identify patients with nonalcoholic steatohepatitis at high risk of adverse outcomes: Expert panel recommendations. Am. J. Gastroenterol. 116, 254\u2013262 (2021).","journal-title":"Am. J. Gastroenterol."},{"key":"24910_CR11","unstructured":"Graupera, I. et al. Low accuracy of FIB-4 and NAFLD fibrosis scores for screening for liver fibrosis in the population. Clin. Gastroenterol. Hepatol. (2021)."},{"key":"24910_CR12","doi-asserted-by":"publisher","first-page":"e986","DOI":"10.1097\/MEG.0000000000002340","volume":"33","author":"D Ouzan","year":"2021","unstructured":"Ouzan, D. et al. Prospective screening for significant liver fibrosis by fibrosis-4 in primary care patients without known liver disease. Eur. J. Gastroenterol. Hepatol. 33, e986\u2013e991 (2021).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"24910_CR13","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","volume":"323","author":"AC Sheka","year":"2020","unstructured":"Sheka, A. C. et al. Nonalcoholic steatohepatitis: A review. JAMA 323, 1175\u20131183 (2020).","journal-title":"JAMA"},{"key":"24910_CR14","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling, R. K. et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology 43, 1317\u20131325 (2006).","journal-title":"Hepatology"},{"key":"24910_CR15","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1053\/j.gastro.2019.09.008","volume":"158","author":"H Hagstr\u00f6m","year":"2020","unstructured":"Hagstr\u00f6m, H., Talb\u00e4ck, M., Andreasson, A., Walldius, G. & Hammar, N. Ability of noninvasive scoring systems to identify individuals in the population at risk for severe liver disease. Gastroenterology 158, 200\u2013214 (2020).","journal-title":"Gastroenterology"},{"key":"24910_CR16","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jhep.2020.06.007","volume":"73","author":"H Hagstr\u00f6m","year":"2020","unstructured":"Hagstr\u00f6m, H., Talb\u00e4ck, M., Andreasson, A., Walldius, G. & Hammar, N. Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease. J. Hepatol. 73, 1023\u20131029 (2020).","journal-title":"J. Hepatol."},{"key":"24910_CR17","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s00535-018-1532-5","volume":"54","author":"R Tateishi","year":"2019","unstructured":"Tateishi, R. et al. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011\u20132015 Update. J. Gastroenterol. 54, 367\u2013376 (2019).","journal-title":"J. Gastroenterol."},{"key":"24910_CR18","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1053\/j.gastro.2018.10.024","volume":"156","author":"TF Baumert","year":"2019","unstructured":"Baumert, T. F., Berg, T., Lim, J. K. & Nelson, D. R. Status of direct-acting antiviral therapy for hepatitis C virus infection and remaining challenges. Gastroenterology 156, 431\u2013445 (2019).","journal-title":"Gastroenterology"},{"key":"24910_CR19","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/hep.23785","volume":"52","author":"TT Chang","year":"2010","unstructured":"Chang, T. T. et al. Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52, 886\u2013893 (2010).","journal-title":"Hepatology"},{"key":"24910_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","volume":"1","author":"HL Chan","year":"2016","unstructured":"Chan, H. L. et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol. Hepatol. 1, 185\u2013195 (2016).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"24910_CR21","doi-asserted-by":"publisher","first-page":"426","DOI":"10.2188\/jea.JE20200416","volume":"31","author":"K Katanoda","year":"2021","unstructured":"Katanoda, K. et al. Updated trends in cancer in Japan: Incidence in 1985\u20132015 and mortality in 1958\u20132018\u2014A sign of decrease in cancer incidence. J. Epidemiol. 31, 426\u2013450 (2021).","journal-title":"J. Epidemiol."},{"key":"24910_CR22","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s00535-020-01748-x","volume":"56","author":"H Enomoto","year":"2021","unstructured":"Enomoto, H. et al. The transition in the etiologies of hepatocellular carcinoma-complicated liver cirrhosis in a nationwide survey of Japan. J. Gastroenterol. 56, 158\u2013167 (2021).","journal-title":"J. Gastroenterol."},{"key":"24910_CR23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00535-019-01645-y","volume":"55","author":"H Enomoto","year":"2020","unstructured":"Enomoto, H. et al. Transition in the etiology of liver cirrhosis in Japan: A nationwide survey. J. Gastroenterol. 55, 353\u2013362 (2020).","journal-title":"J. Gastroenterol."},{"key":"24910_CR24","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/hep.510290347","volume":"29","author":"SH Caldwell","year":"1999","unstructured":"Caldwell, S. H. et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29, 664\u2013669 (1999).","journal-title":"Hepatology"},{"key":"24910_CR25","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","volume":"7","author":"AG Shah","year":"2009","unstructured":"Shah, A. G. et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 7, 1104\u20131112 (2009).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"24910_CR26","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1111\/hepr.12647","volume":"46","author":"W Sun","year":"2016","unstructured":"Sun, W. et al. Comparison of FIB-4 index, NAFLD fibrosis score and Bard score for prediction of advanced fibrosis in adult patients with non-alcoholic fatty liver disease: A meta-analysis study. Hepatol. Res. 46, 862\u2013870 (2016).","journal-title":"Hepatol. Res."},{"key":"24910_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234433","volume":"15","author":"T Shimamoto","year":"2020","unstructured":"Shimamoto, T. et al. The association of Helicobacter pylori infection with serum lipid profiles: An evaluation based on a combination of meta-analysis and a propensity score-based observational approach. PLoS ONE 15, e0234433 (2020).","journal-title":"PLoS ONE"},{"key":"24910_CR28","unstructured":"Weir, C. B. & Jan, A. BMI Classification Percentile and Cut off Points. StatPearls (Treasure Island (FL), 2021)."},{"key":"24910_CR29","first-page":"85","volume":"27","author":"TE Raghunathan","year":"2001","unstructured":"Raghunathan, T. E. et al. A multivariate technique for multiply imputing missing values using a sequence of regression models. Surv. Methodol. 27, 85\u201395 (2001).","journal-title":"Surv. Methodol."},{"key":"24910_CR30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox, D. R. Regression models and life-tables. J. R. Stat. Soc. B 34, 187\u2013202 (1972).","journal-title":"J. R. Stat. Soc. B"},{"key":"24910_CR31","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1214\/aos\/1176345976","volume":"10","author":"PK Andersen","year":"1982","unstructured":"Andersen, P. K. & Gill, R. D. Cox\u2019s regression model for counting process: A large sample study. Ann. Stat. 10, 1100\u20131120 (1982).","journal-title":"Ann. Stat."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24910-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24910-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24910-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T15:56:26Z","timestamp":1728489386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-24910-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,27]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["24910"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-24910-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,27]]},"assertion":[{"value":"2 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20357"}}